Biosimilars from Samsung Bioepis have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists.
Recent clinical and real world evidence for Samsung Bioepis biosimilars for bevacizumab and trastuzumab support use of these products in place of the reference versions, David Planchard, MD, and Mark D. Pegram, MD, said at the European Society for Medical Oncology Congress Virtual 2020, in a review of study findings.1
“People may know that biosimilars save money overall, but want to see that the data prove clinical similarity in a very controlled setting as well as in the real world,” said David Planchard, MD, of Institut Gustave Roussy (IGR) in Villejuif, France. Planchard serves as associate professor of medicine with the Thoracic Tumor Board at IGR.
The Samsung Bioepis bevacizumab biosimilar Aybintio (SB8) was approved in August for marketing by the European Commission. Samsung Bioepis’ trastuzumab biosimilar Ontruzant was launched in the United States in April.
Planchard noted that SB8 and the bevacizumab reference product (Avastin, BEV) have an “identical primary amino acid sequence and have demonstrated highly similar structural, physiochemical and biological properties.” A phase 3 trial randomized 763 patients with non–small cell lung cancer roughly equally to SB8 and BEV.1,2 Of those, 258 completed induction treatment with SB8 and 277 with BEV. The mean age of patients was 60.2 vs 60 in the respective arms.
In the full analysis set (FAS), equivalence was demonstrated in terms of best overall response rate (ORR) risk ratio and risk difference. The ORR in the FAS was 47.6% for SB8 vs 42.8% for BEV. In the per protocol set (PPS), the best ORR was 50.1% for SB8 vs 44.8% for BEV.
Median progression-free survival (PFS) in the FAS was 8.5 months for SB8 vs 7.9 months for BEV, and in PPS the median PFS was 8.5 months vs 7.9 months, respectively. Median overall survival (OS) in the FAS was 14.9 months vs 15.8 months, respectively; and in PPS, 14.8 months vs 15.8 months. Mean duration of response was 6.38 months vs 6.79 months, respectively, in the FAS; and 6.33 months vs 6.81 months in PPS.
Tumor burden change at 24-weeks from start of induction therapy in FAS was 0.6% (95% CI, –4.18% to 2.99%).
Overall responses also helped to demonstrate comparative efficacy in the trial arms. At cycle 2, there were 96 (28.5%) partial responses (PRs) in the SB8 group vs 88 (26.8%) in the BEV group; and stable disease was achieved by 202 (59.9%) and 201 (61.3%), respectively.
By cycle 6, the numbers were still close, demonstrating comparability. There were 97 (57.1%) and 83 (49.4%) PRs, respectively; and 60 (35.3%) and 70 (41.7%) SDs, Planchard said. At cycle 6, there was 1 (0.6%) complete response in the BEV group.
In terms of treatment emergent adverse events of special interest, proteinuria was observed in 2 instances in the SB8 arm (0.5%) and 7 patients (1.8%) in the BEV group. Hypertension was noted in 29 (7.7%) and 16 (4.2%) of each group, respectively.
Pharmacokinetic profiles also were highly comparable, Planchard said.
Pegram, director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, Stanford University Cancer Institute, California, discussed real world data for biosimilar trastuzumab (SB3, Ontruzant) plus reference pertuzumab in early stage breast cancer.
He noted that a 56% pathological complete response rate (pCR) was noted in 215 Danish patients with HER2-positive breast cancer who received neoadjuvant chemotherapy plus SB3 plus pertuzumab, which he said was exactly comparable to historical trial evidence for the reference drug (Herceptin).
“Indeed, 68% of patients treated in the neoadjuvant setting with node-positive disease converted from lymph node–positive disease to lymph node–negative disease after treatment, so that’s also very reassuring and demonstrates the activity of this trastuzumab biosimilar when combined with pertuzumab,” he said.1
In a separate study involving real-world outcomes of 35 patients from Austria with HER2-positive breast cancer who received chemotherapy plus SB3 plus pertuzumab, the safety and efficacy profile of SB3 plus pertuzumab was consistent with that of the reference product in that combination. Significantly, 22 patients treated in the neoadjuvant setting achieved a pCR of 50%; none of the 35 patients had a decline in left ventricular ejection fraction (LVEF) of more than 10%; and 2 patients had an LVEF decline of ≤ 5% after treatment. “This is also very reassuring in terms of cardiac safety signals,” Pegram said.1
Importantly, Pegram said, “this recent real-world evidence supports the extrapolation of trastuzumab-dttb [SB3] to include combination [therapy] with pertuzumab.”
Reference
1. Planchard D, Pegram MD. Navigating the optimized oncology treatment options in colorectal cancer, lung cancer and breast cancer through multidisciplinary discussions: clinical evidences of biosimilars. Presented at: ESMO Congress Virtual 2020. 5389.
2. Reck M, Luft A, Bondarenko I, et al. A phase III randomized double-blind multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer. 2020.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.